High-throughput high-content nanoscale extracellular vesicle analysis
Active Project Grant Awarded Last action
- Award ID
- R43GM156162
- Recipient
-
Numentus Technologies Inc. UEI HGYJGDEE8CM6
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $298,999
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date 77% complete
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- There is growing recognition that extracellular vesicles (EVS)¾micrometer- or nanometer-sized lipid particles containing protein and nucleic acid cargoes (information)¾are highly promising for new diagnostics/prognostics and experimental therapies. There is, however, a key unmet need for technical platforms able to solve a fundamental problem confounding the exploitation of EV information in biology and medicine. That is, because EV populations are naturally complex and thus heterogeneous, IT can be challenging to detect and characterize unique subpopulations-of-interest present only at low abundance in a sample containing other (normal) EVS from, e.g., a host. In this phase i project, we will apply a novel technology platform designed to address the problem of resolving multiple EV subpopulations at the single- particle level by directly identifying specific surface proteins of dispersed particles, through rapid highly- multiplexed fluorescence imaging analysis we have chosen to focus on analyzing medically important categories of EVS called exosomes (here from human cancer cells) and outer membrane vesicles (omvs; from bacterial cells). Our goal ultimately is to develop a unique imaging platform for the high-content, high- throughput analysis of the surface proteins of single exosomes or omvs present in clinically relevant specimens. Briefly, our innovative platform will simultaneously analyze, in one pass, up to 10 known or potential exosome/OMV surface markers in up to 107 dispersed particles obtained from a biofluid such as blood, saliva, or stool. Unlike conventional methods, our platform can rapidly: a) analyze diverse EVS; b) simultaneously read multiple protein surface markers (cargoes) and thus detect subpopulations-of-interest; c) read single particle protein surface cargoes, greatly raising information yield compared to typical bulk methods producing pooled cargo data; and d) identify exosome/OMV subpopulations based on unique combinations of biomarkers from points a-c. We propose three stepwise aims in development of a highly multiplexed, high throughput platform for nano-scale EV detection: (1) construction of the instrument based on an existing high speed hyperspectral designed specifically for cells and tissue sections; (2) testing and calibration of the platform using fluorescent nanoparticles and fluorescently labeled liposomes; and (3) application of the platform to detecting exosomes from human cancer cell lines or omvs from gram-negative and gram-positive bacteria (represented by e. Coli and s. Aureus, respectively). We anticipate that our platform could become a new tool for EV research; a new diagnostic/prognostic tool for studying and managing pathologies in which EV analysis is clinically informative; and a novel method for monitoring normal or aberrant microbiome status.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $298,999 |
Quick answers
Who received award R43GM156162?
R43GM156162 was awarded to Numentus Technologies Inc. by National Institute of General Medical Sciences (National Institutes of Health) on July 5, 2024.
How much is award R43GM156162 worth?
$298,999 has been obligated on R43GM156162.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award